title: Comparison of tolerability and adverse events following treatment with two GnRH agonists in patients with advanced prostate cancer.
abstract: This multicenter, randomized, crossover, open-label study (ClinicalTrials.gov identifier: NCT01161563) assessed patients'and clinicians'perceptions of injection site tolerability and adverse events following the intramuscular injection of triptorelin pamoate or subcutaneous injection of leuprolide acetate in 107 male, patients with advanced prostate cancer.
authors.affiliation: Atlantic Urology Clinics, USA.
authors.forename: Neal D
authors.initials: ND
authors.lastname: Shore
authors.affiliation: Lancaster Urology, Lancaster, PA, USA.
authors.forename: Paul
authors.initials: P
authors.lastname: Sieber
authors.affiliation: Lancaster Urology, Lancaster, PA, USA.
authors.forename: Leanne
authors.initials: L
authors.lastname: Schimke
authors.affiliation: Delaware Valley Urology, Mt. Laurel, NJ, USA.
authors.forename: Adam
authors.initials: A
authors.lastname: Perzin
authors.affiliation: Watson Pharmaceuticals, Salt Lake City, UT, USA.
authors.forename: Scott
authors.initials: S
authors.lastname: Olsen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects; D018592:Cross-Over Studies; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D016729:Leuprolide / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000451:nursing; D017329:Triptorelin Pamoate / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D016729:Leuprolide